

Financial Tear Sheet

Corporate Profile

MiMedx® is an integrated developer, processor and marketer of patent protected and proprietary regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues and human skin and bone.

"Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. The MiMedx allograft product families include our: dHACM family with AmnioFix®, EpiFix® and EpiBurn® brands; Amniotic Fluid family with OrthoFlo brand; Umbilical family with EpiCord™ and AmnioCord™ brands; Placental Collagen family with CollaFix™ and AmnioFill™ brands; Bone family with Physio® brand; and Skin family with AlloBurn™ brand. AmnioFix, EpiFix, and EpiBurn are our tissue technologies processed from human amniotic membrane; OrthoFlo is an amniotic fluid derived allograft; EpiCord™ and AmnioCord™ are derived from the umbilical cord; Physio is a unique bone grafting material comprised of 100% bone tissue with no added carrier; AlloBurn is a skin product derived from human skin designed for the treatment of burns; and CollaFix, our next brand we plan to commercialize, is our collagen fiber technology, developed with our patented cross-linking polymers, designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair. We process the human amniotic membrane utilizing our proprietary PURION® Process, to produce a safe and effective implant. MiMedx proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization. MiMedx is the leading supplier of amniotic tissue, having supplied over 700,000 allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare.

Primary IR Contact

Michael J. Senken
Chief Financial Officer
MiMedx Group, Inc.

Phone: 770-651-9066

E-mail:

investorrelations@mimedx.com

Stock Performance

MDXG (Common Stock)

Exchange	NASDAQ CM (US Dollar)
Price	\$15.30
Change (%)	▲ 0.43 (2.89%)
Volume	948,895
52 Week Low	\$6.94
Market Cap	\$1,696,323,638
Rolling EPS	0.14
PE Ratio	109.286
Shares Outstanding	110,870,826

Data as of Jun 28, 2017 4:00 p.m. ET

■ MIMEDX GROUP INC
as of 6/27/2017



EDGAROnline

Recent Headlines & Events

Jun 15, 2017 - 12:57 p.m.

[Scientific And Clinical Review Confirms Potential Of MiMedx dHACM Allografts For Regenerative Applications In Orthopedics](#)

Jun 13, 2017 - 3:30 p.m.

[MiMedx Amniofix® data showing colorectal anastomotic leak rate reduction presented at ASCRS Meeting](#)

Jun 01, 2017 - 9:02 a.m.

[MiMedx to Present at the Jefferies 2017 Global Healthcare Conference](#)

There are currently no events scheduled.

SEC Filings

Filing Date	Form
Jun 16, 2017	4
May 30, 2017	4
May 19, 2017	4
May 19, 2017	4

Corporate Governance

Parker "Pete" H. Petit	Chairman and Chief Executive Officer
William C. Taylor	President and Chief Operating Officer
Michael J. Senken	Chief Financial Officer
Alexandra Haden	General Counsel and Secretary
Christopher M. Cashman	EVP and Chief Commercialization Officer
Deborah L. Dean	Executive Vice President
Brent Miller	Executive Vice President
Thornton A. Kuntz	Senior Vice President of Administration
Michael W. Carlton	Senior Vice President of Global Sales
Marlene M. DeSimone	Senior Vice President of Corporate Strategic Development
Donald E. Fetterolf, M.D., FACP	Chief Medical Officer
Thomas J. Koob, PhD	Chief Scientific Officer
Frank Burrows	Vice President of Clinical and Scientific Liaison
Rebecca J. C. Brown, Ph.D.	Vice President of Product Development
Randall Spencer	Vice President of Clinical Innovation
David H. Mason, Jr., M.D.	Vice President of Medical Affairs for Clinical Practice

Powered By **EDGAR**Online

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed